These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
299 related articles for article (PubMed ID: 29779024)
1. A Randomized Clinical Trial of Metformin to Treat Autosomal Dominant Polycystic Kidney Disease. Seliger SL; Abebe KZ; Hallows KR; Miskulin DC; Perrone RD; Watnick T; Bae KT Am J Nephrol; 2018; 47(5):352-360. PubMed ID: 29779024 [TBL] [Abstract][Full Text] [Related]
2. Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study. Brosnahan GM; Wang W; Gitomer B; Struemph T; George D; You Z; Nowak KL; Klawitter J; Chonchol MB Am J Kidney Dis; 2022 Apr; 79(4):518-526. PubMed ID: 34391872 [TBL] [Abstract][Full Text] [Related]
3. Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease. Gevers TJ; Chrispijn M; Wetzels JF; Drenth JP BMC Nephrol; 2012 Apr; 13():17. PubMed ID: 22475206 [TBL] [Abstract][Full Text] [Related]
4. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease. van Aerts RMM; Kievit W; D'Agnolo HMA; Blijdorp CJ; Casteleijn NF; Dekker SEI; de Fijter JW; van Gastel M; Gevers TJ; van de Laarschot LFM; Lantinga MA; Losekoot M; Meijer E; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Visser FW; Wetzels JF; Zietse R; Gansevoort RT; Drenth JPH; Gastroenterology; 2019 Aug; 157(2):481-491.e7. PubMed ID: 31022403 [TBL] [Abstract][Full Text] [Related]
5. Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial. Hogan MC; Chamberlin JA; Vaughan LE; Waits AL; Banks C; Leistikow K; Oftsie T; Madsen C; Edwards M; Glockner J; Kremers WK; Harris PC; LaRusso NF; Torres VE; Masyuk TV Clin J Am Soc Nephrol; 2020 Sep; 15(9):1267-1278. PubMed ID: 32843370 [TBL] [Abstract][Full Text] [Related]
6. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial. Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Wetzels JF; Drenth JP Liver Int; 2015 May; 35(5):1607-14. PubMed ID: 25369108 [TBL] [Abstract][Full Text] [Related]
8. A single-arm pilot study of metformin in patients with autosomal dominant polycystic kidney disease. Sorohan BM; Ismail G; Andronesi A; Micu G; Obrișcă B; Jurubiță R; Sinescu I; Baston C BMC Nephrol; 2019 Jul; 20(1):276. PubMed ID: 31337351 [TBL] [Abstract][Full Text] [Related]
9. Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD). Perrone RD; Abebe KZ; Watnick TJ; Althouse AD; Hallows KR; Lalama CM; Miskulin DC; Seliger SL; Tao C; Harris PC; Bae KT Kidney Int; 2021 Sep; 100(3):684-696. PubMed ID: 34186056 [TBL] [Abstract][Full Text] [Related]
10. Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model. Pastor-Soler NM; Li H; Pham J; Rivera D; Ho PY; Mancino V; Saitta B; Hallows KR Am J Physiol Renal Physiol; 2022 Jan; 322(1):F27-F41. PubMed ID: 34806449 [TBL] [Abstract][Full Text] [Related]
11. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. van Keimpema L; Nevens F; Vanslembrouck R; van Oijen MG; Hoffmann AL; Dekker HM; de Man RA; Drenth JP Gastroenterology; 2009 Nov; 137(5):1661-8.e1-2. PubMed ID: 19646443 [TBL] [Abstract][Full Text] [Related]
12. Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease. Meijer E; Drenth JP; d'Agnolo H; Casteleijn NF; de Fijter JW; Gevers TJ; Kappert P; Peters DJ; Salih M; Soonawala D; Spithoven EM; Torres VE; Visser FW; Wetzels JF; Zietse R; Gansevoort RT; Am J Kidney Dis; 2014 Mar; 63(3):446-55. PubMed ID: 24342522 [TBL] [Abstract][Full Text] [Related]
13. Yinang formulation versus placebo granules as a treatment for chronic kidney disease stages III-IV in patients with autosomal dominant polycystic kidney disease: study protocol for a double-blind placebo-controlled randomized clinical trial. Gan J; Wu Y; Gong X; Ma Y; Yu S; Gao J Trials; 2019 Aug; 20(1):481. PubMed ID: 31391092 [TBL] [Abstract][Full Text] [Related]
14. Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial. Schaefer F; Mekahli D; Emma F; Gilbert RD; Bockenhauer D; Cadnapaphornchai MA; Shi L; Dandurand A; Sikes K; Shoaf SE Eur J Pediatr; 2019 Jul; 178(7):1013-1021. PubMed ID: 31053954 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease. Hogan MC; Masyuk T; Bergstralh E; Li B; Kremers WK; Vaughan LE; Ihrke A; Severson AL; Irazabal MV; Glockner J; LaRusso NF; Torres VE Mayo Clin Proc; 2015 Aug; 90(8):1030-7. PubMed ID: 26166166 [TBL] [Abstract][Full Text] [Related]
16. Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial. Meijer E; Visser FW; van Aerts RMM; Blijdorp CJ; Casteleijn NF; D'Agnolo HMA; Dekker SEI; Drenth JPH; de Fijter JW; van Gastel MDA; Gevers TJ; Lantinga MA; Losekoot M; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Wetzels JF; Zietse R; Gansevoort RT; JAMA; 2018 Nov; 320(19):2010-2019. PubMed ID: 30422235 [TBL] [Abstract][Full Text] [Related]
17. Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials. Brosnahan GM; Abebe KZ; Rahbari-Oskoui FF; Patterson CG; Bae KT; Schrier RW; Braun WE; Chapman AB; Flessner MF; Harris PC; Perrone RD; Steinman TI; Torres VE; Curr Hypertens Rev; 2017; 13(2):109-120. PubMed ID: 28460625 [TBL] [Abstract][Full Text] [Related]
18. Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial. Perico N; Ruggenenti P; Perna A; Caroli A; Trillini M; Sironi S; Pisani A; Riccio E; Imbriaco M; Dugo M; Morana G; Granata A; Figuera M; Gaspari F; Carrara F; Rubis N; Villa A; Gamba S; Prandini S; Cortinovis M; Remuzzi A; Remuzzi G; PLoS Med; 2019 Apr; 16(4):e1002777. PubMed ID: 30951521 [TBL] [Abstract][Full Text] [Related]
19. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial. Chrispijn M; Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Drenth JP J Hepatol; 2013 Jul; 59(1):153-9. PubMed ID: 23499726 [TBL] [Abstract][Full Text] [Related]
20. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]